-
Trastuzumab
- indication:For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
- pharmacologypharmacology:
- mechanism: Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
- toxicity: Administration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclophosphamide therapy.
- absorprion:
- halflife: average 28.5 days
- roouteelimination:
- volumedistribution: * 44 mL/kg
- clearance: